PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CHMP recommend Saphnelo for systematic lupus erythematosus

With approval, Saphnelo would be the first available treatment for systematic lupus erythematosus in Europe in over ten years.

Saphnelo (anifrolumab), a first-in-class type 1 interferon receptor antibody, has been recommended for marketing authorisation in the EU. The drug has been recommended as an add-on therapy for the treatment of adult patients with moderate-to-severe active autoantibody-positive systemic lupus erythematosus (SLE) alongside standard therapy.

AstraZeneca’s Saphnelo has demonstrated efficacy in reducing overall disease activity in patients with systemic lupus erythematosus. The European Medicine Agency’s Comittee for Medicinal Products for Human Use (CHMP) based its positive opinion on results from the Saphnelo clinical development programme, including the TULIP phase 3 trials and the MUSE phase 2 trial.

More patients treated with Saphnelo in these trials experienced a reduction in overall disease activity across organ systems and achieved sustained reduction in oral corticosteroid (OCS) use, compared to placebo. Both groups also received standard therapy.

Ian Bruce, Professor of Rheumatology at the University of Manchester and steering committee chair for the Saphnelo SLE clinical development programme said: “Systemic lupus erythematosus is a complex and heterogeneous disease that can have a debilitating impact on a person’s quality of life. We need new treatments that are effective in reducing underlying disease activity for patients, particularly those who require higher doses of oral corticosteroids, which themselves can be damaging in the long term. The anifrolumab clinical programme has provided compelling evidence that this medicine has the potential to be an important new option for patients.”

SLE is a complex autoimmune condition that can affect any bodily organs. Patients of SLE often experience inadequate disease control, long-term organ damage and poor health-related quality of life.

SLE is the most common type of lupus and is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. If approved, Saphnelo would be the first new treatment for SLE in Europe in more than a decade.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026